NY-UBS/BLOOMBERG
27.2.2020 14:32:05 CET | Business Wire | Press release
UBS and Bloomberg announce the launch of "Girls Take Finance," a global initiative that expands the 2019 "Girls Take" events to 12 cities worldwide. "Girls Take Finance" aims to inspire the next-generation of leaders by providing young women, aged 14-18, with insight into the financial services industry and career opportunities in business, finance and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005522/en/
In 2020, UBS and Bloomberg will expand "Girls Take Finance" to major cities across the globe, including Frankfurt, Jakarta, Johannesburg, London, San Francisco, São Paulo, Sydney, and Zurich.
"As someone who started his career in financial services as an apprentice at age 15, I know first-hand how important encouragement is to making career choices," said UBS Group CEO Sergio P. Ermotti. "That's why I'm so delighted to expand the program this year. Together with Bloomberg, we can inspire hundreds of young women who otherwise might not have seriously considered pursuing careers in areas like finance, banking and technology."
As with the previous "Girls Take" events, UBS and Bloomberg are partnering with local non-profits in each city to host on-site events at some of the world's most iconic locations in business and finance. The full-day programming will include workshops focused on career growth and networking skills, panel discussions with industry experts, and motivational talks with volunteers about the variety of careers in financial services.
“Businesses that want to attract tomorrow’s brightest talent must do more to make careers in their industry accessible to more diverse groups at an earlier age,” said Peter T. Grauer, Chairman of Bloomberg LP and Founding Chairman of the U.S. 30% Club. “We’re glad to participate in 'Girls Take Finance' and are excited to expand the program’s footprint in its second year so that more young women can see a future for themselves in our industry, which is eager for their talent and perspective.”
The initiative builds on the success of the inaugural "Girls Take" events, which began March 2019 as "Girls Take Wall Street " in New York City, where UBS, Bloomberg and State Street Global Advisors convened more than 100 high school girls for a day of educational career mentorship. The day ended with the girls ringing The Closing Bell® at the New York Stock Exchange to commemorate the start of Women's History Month.
In October 2019, UBS and Bloomberg took "Girls Take Wall Street" to India, hosting "Girls Take Dalal Street" in Mumbai and "Girls Take GIFT City" in Ahmedabad . Nearly 150 young women from colleges across Mumbai, Pune and Ahmedabad participated in the mentoring events. Students also had the opportunity to ring the Closing Bell at the Bombay Stock Exchange and visited the India International Exchange (INX), India’s first international stock exchange.
Additionally, UBS and Bloomberg have standalone initiatives that focus on helping young people advance their education and future careers.
UBS is committed to taking a leading role in driving change that matters in the world. Through strategic financial commitments and targeted employee volunteering to advance education, the firm is dedicated to empowering the next generation of young people. This is demonstrated through efforts across the firm's Community Affairs programs, including The Bridge Academy in the UK, Keys To Your Future: College and Career Readiness in the US, YES (Young Enterprise Switzerland) in Switzerland and UBS Community Academies in APAC. A pioneer in social finance, the UBS Optimus Foundation takes a leading role in driving impactful philanthropy that delivers breakthrough solutions to social and environmental issues. UBS is also a founding partner of #TOGETHERBAND , a campaign with the Bottletop Foundation that aims to promote the United Nations Sustainable Development Goals (SDGs), to achieve a more sustainable world by 2030. The #TOGETHERBAND campaign will launch SDG5, Gender Equality and Women's Empowerment in March to coincide with the initiative.
Bloomberg Startup, the company’s global philanthropic education engagement program, supports young women around the world by providing access to mentors, internships, and career-readiness workshops that expose students to diverse and influential women. Read more about how Bloomberg is advancing women: https://www.bloomberg.com/women .
Confirmed 2020 "Girls Take Finance" Non-Profit Partners:
City & Date: |
Non-Profit Partner: |
|||
London, UK – March 2 |
||||
San Francisco, US – March 4 |
||||
New York, US – March 6 |
||||
Zurich, CH – March 6 |
||||
Johannesburg, ZA – March 6 |
||||
Sydney, AU – March 12 |
ABCN and CareerTrackers |
|||
São Paulo, BR – March 17 |
||||
Frankfurt, DE – March 20 |
||||
Bangkok, TH – August |
Later in 2020, UBS and Bloomberg will also bring Girls Take Finance to Indonesia and India, hosting events in Jakarta, Mumbai and GIFT City.
Notes to Editors
About UBS
UBS provides financial advice and solutions to wealthy, institutional and corporate clients worldwide, as well as private clients in Switzerland. UBS's strategy is centered on our leading global wealth management business and our premier universal bank in Switzerland, enhanced by Asset Management and the Investment Bank. The bank focuses on businesses that have a strong competitive position in their targeted markets, are capital efficient, and have an attractive long-term structural growth or profitability outlook.
About Bloomberg
Bloomberg, the global business and financial information and news leader, gives influential decision makers a critical edge by connecting them to a dynamic network of information, people and ideas. The company’s strength – delivering data, news and analytics through innovative technology, quickly and accurately – is at the core of the Bloomberg Terminal. Bloomberg’s enterprise solutions build on the company’s core strength: leveraging technology to allow customers to access, integrate, distribute and manage data and information across organizations more efficiently and effectively. For more information, visit www.bloomberg.com or request a demo .
© UBS 2020. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005522/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
